Literature DB >> 27776263

Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly.

Annamaria Cattaneo1, Nadia Cattane2, Samantha Galluzzi3, Stefania Provasi2, Nicola Lopizzo2, Cristina Festari3, Clarissa Ferrari2, Ugo Paolo Guerra4, Barbara Paghera5, Cristina Muscio6, Angelo Bianchetti7, Giorgio Dalla Volta8, Marinella Turla9, Maria Sofia Cotelli9, Michele Gennuso10, Alessandro Prelle10, Orazio Zanetti2, Giulia Lussignoli2, Dario Mirabile11, Daniele Bellandi12, Simona Gentile13, Gloria Belotti14, Daniele Villani15, Taoufiq Harach16, Tristan Bolmont17, Alessandro Padovani18, Marina Boccardi3, Giovanni B Frisoni19.   

Abstract

The pathway leading from amyloid-β deposition to cognitive impairment is believed to be a cornerstone of the pathogenesis of Alzheimer's disease (AD). However, what drives amyloid buildup in sporadic nongenetic cases of AD is still unknown. AD brains feature an inflammatory reaction around amyloid plaques, and a specific subset of the gut microbiota (GMB) may promote brain inflammation. We investigated the possible role of the GMB in AD pathogenesis by studying the association of brain amyloidosis with (1) GMB taxa with pro- and anti-inflammatory activity; and (2) peripheral inflammation in cognitively impaired patients. We measured the stool abundance of selected bacterial GMB taxa (Escherichia/Shigella, Pseudomonas aeruginosa, Eubacterium rectale, Eubacterium hallii, Faecalibacterium prausnitzii, and Bacteroides fragilis) and the blood expression levels of cytokines (pro-inflammatory cytokines: CXCL2, CXCL10, interleukin [IL]-1β, IL-6, IL-18, IL-8, inflammasome complex (NLRP3), tumor necrosis factor-alpha [TNF-α]; anti-inflammatory cytokines: IL-4, IL-10, IL-13) in cognitively impaired patients with (n = 40, Amy+) and with no brain amyloidosis (n = 33, Amy-) and also in a group of controls (n = 10, no brain amyloidosis and no cognitive impairment). Amy+ patients showed higher levels of pro-inflammatory cytokines (IL-6, CXCL2, NLRP3, and IL-1β) compared with both controls and with Amy- patients. A reduction of the anti-inflammatory cytokine IL-10 was observed in Amy+ versus Amy-. Amy+ showed lower abundance of E. rectale and higher abundance of Escherichia/Shigella compared with both healthy controls (fold change, FC = -9.6, p < 0.001 and FC = +12.8, p < 0.001, respectively) and to Amy- (FC = -7.7, p < 0.001 and FC = +7.4, p = 0.003). A positive correlation was observed between pro-inflammatory cytokines IL-1β, NLRP3, and CXCL2 with abundance of the inflammatory bacteria taxon Escherichia/Shigella (rho = 0.60, p < 0.001; rho = 0.57, p < 0.001; and rho = 0.30, p = 0.007, respectively) and a negative correlation with the anti-inflammatory E. rectale (rho = -0.48, p < 0.001; rho = -0.25, p = 0.024; rho = -0.49, p < 0.001). Our data indicate that an increase in the abundance of a pro-inflammatory GMB taxon, Escherichia/Shigella, and a reduction in the abundance of an anti-inflammatory taxon, E. rectale, are possibly associated with a peripheral inflammatory state in patients with cognitive impairment and brain amyloidosis. A possible causal relation between GMB-related inflammation and amyloidosis deserves further investigation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain amyloidosis; Cognitive impairment; Gut microbiota; Inflammation; Neurodegeneration

Mesh:

Substances:

Year:  2016        PMID: 27776263     DOI: 10.1016/j.neurobiolaging.2016.08.019

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  270 in total

Review 1.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

2.  Elevated amyloidoses of human IAPP and amyloid beta by lipopolysaccharide and their mitigation by carbon quantum dots.

Authors:  Kairi Koppel; Huayuan Tang; Ibrahim Javed; Mehrdad Parsa; Monika Mortimer; Thomas P Davis; Sijie Lin; Alan L Chaffee; Feng Ding; Pu Chun Ke
Journal:  Nanoscale       Date:  2020-06-18       Impact factor: 7.790

Review 3.  Gut Microbiota Disorder, Gut Epithelial and Blood-Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways.

Authors:  Menizibeya O Welcome
Journal:  Neuromolecular Med       Date:  2019-05-21       Impact factor: 3.843

Review 4.  The gut microbiota-brain axis in behaviour and brain disorders.

Authors:  Livia H Morais; Henry L Schreiber; Sarkis K Mazmanian
Journal:  Nat Rev Microbiol       Date:  2020-10-22       Impact factor: 60.633

5.  Feasibility of fecal microbiota transplantation via oral gavage to safely alter gut microbiome composition in marmosets.

Authors:  Corinna N Ross; Kelly R Reveles
Journal:  Am J Primatol       Date:  2020-09-24       Impact factor: 2.371

Review 6.  Microbiota-Brain-Gut Axis and Neurodegenerative Diseases.

Authors:  Eamonn M M Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2017-10-17       Impact factor: 5.081

Review 7.  Dietary Patterns, Physical Activity, Sleep, and Risk for Dementia and Cognitive Decline.

Authors:  Chen Zhao; James M Noble; Karen Marder; Jacob S Hartman; Yian Gu; Nikolaos Scarmeas
Journal:  Curr Nutr Rep       Date:  2018-12

Review 8.  Obstructive Sleep Apnea-Induced Hypertension: Role of the Gut Microbiota.

Authors:  David J Durgan
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

9.  Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats.

Authors:  Thomas W Buford; Yi Sun; Lisa M Roberts; Anisha Banerjee; Sujitha Peramsetty; Anthony Knighton; Amrisha Verma; Drake Morgan; Gonzalo E Torres; Qiuhong Li; Christy S Carter
Journal:  Geroscience       Date:  2020-05-26       Impact factor: 7.713

10.  Prebiotics, Probiotics, and Acetate Supplementation Prevent Hypertension in a Model of Obstructive Sleep Apnea.

Authors:  Bhanu P Ganesh; James W Nelson; Joshua R Eskew; Arunkumar Ganesan; Nadim J Ajami; Joseph F Petrosino; Robert M Bryan; David J Durgan
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.